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Evidence linking glycated albumin to altered glomerular
nephrin and VEGF expression, proteinuria, and diabetic
nephropathy.
Background. Albumin modified by Amadori-glucose
adducts has been linked to the development of diabetic
nephropathy through its ability, independent of hyperglycemia,
to activate protein kinase C-b (PKC-b), up-regulate the
transforming growth factor-b (TGF-b) system, and stimulate
expression of extracellular matrix proteins in glomerular
cells, and by the demonstration that reducing the burden of
glycated albumin ameliorates renal structural and functional
abnormalities in the db/db mouse.
Methods. To probe whether the salutary effects consequent to
lowering glycated albumin, which include reduction of albumin-
uria, relate to an influence of the Amadori-modified protein on
nephrin, the podocyte protein critical to regulation of protein
excretion, and on the angiogenic vascular endothelial growth
factor (VEGF), which induces microvascular permeability, dia-
betic db/db mice were treated with a small molecule that inhibits
the nonenzymatic glycation of albumin.
Results. Compared to nondiabetic db/m mice, diabetic con-
trols exhibited increased urinary excretion of albumin and type
IV collagen, elevated renal TGF-b1 protein levels, reduced
glomerular nephrin immunofluorescence and nephrin protein
by immunoblotting, and increased glomerular VEGF immunos-
taining and renal VEGF protein content. Diabetic animals re-
ceiving test compound showed significant lowering of protein-
uria, normalization of renal TGF-b1 protein, and significant
restoration of altered glomerular nephrin and VEGF expres-
sion.
Conclusion. The findings causally implicate the increased gly-
cated albumin associated with the diabetic state in the abnormal
renal nephrin and VEGF expression found in diabetes, thereby
promoting proteinuria and glomerulosclerosis.
The discovery of a mutation of the NPHS1 gene en-
coding nephrin in the congenital nephrotic syndrome of
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the Finnish type [1] opened the door for studies of the
physiologic role of this podocyte protein and of its alter-
ations in glomerular diseases, particularly those associ-
ated with proteinuria. Nephrin localizes to the slit pore
of podocytes, the visceral glomerular epithelial cells that
line the outer aspect of the glomerular basement mem-
brane and contain interdigitated foot processes forming
intercellular junctions in a zipper-like structure known as
the slit diaphragm that regulates the passage of plasma
macromolecules into Bowman’s space [2–5]. Diabetes,
both experimental [6, 7] and human [8–10], is one of
the several diseases involving the glomerulus in which
podocyte injury has been shown to occur. Changes in ep-
ithelial cell structure and decreased number of podocytes
per glomerulus are found in diabetic patients with al-
buminuria and overt proteinuria [11–14]; the density of
podocytes correlates inversely with the albumin excre-
tion rate [15], and decreased podocyte number correlates
with disease progression in type 1 diabetes [13]. These
changes are accompanied by decreased nephrin expres-
sion in both experimental [6, 7] and human diabetes, and
nephrin mRNA inversely correlates with the degree of
proteinuria [9, 16]. The reduced nephrin appears to be
a relatively specific marker of renal disease in diabetes
since the expression of the podocyte proteins CD2AP
and podocin is reportedly normal [10].
A recent report that incubation of glomerular epithe-
lial cells with glycated albumin decreases nephrin ex-
pression [8] prompted the present study in which we
examined whether in vivo reduction of the elevated con-
centrations of glycated albumin associated with diabetes
can positively influence glomerular nephrin. Previous
studies have linked albumin modified by Amadori glu-
cose adducts to the development of diabetic nephropa-
thy through its ability, independent of hyperglycemia, to
activate protein kinase C-b (PKC-b) and extracellular-
regulated kinase (ERK), up-regulate the transforming
growth factor-b (TGF-b) system, and stimulate expres-
sion of extracellular matrix proteins in glomerular cells
[17–21], and by the demonstration that reducing the
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burden of glycated albumin ameliorates renal structural
and functional abnormalities in the db/db mouse [22, 23].
We report that treatment of diabetic db/db mice with a
small molecule that inhibits the nonenzymatic glycation
of albumin [23] prevents glomerular nephrin depletion in
association with a significant lowering of proteinuria. A
concordant relationship was observed between protein-
uria and glomerular expression of the angiogenic vas-
cular endothelial growth factor (VEGF), which induces
microvascular permeability. VEGF was increased in con-
trol diabetic mice and significantly reduced in diabetic
mice treated with test compound.
METHODS
Experimental animals
The studies were performed in male db/db mice and in
age-matched nondiabetic db/m mice obtained from The
Jackson Laboratory (Bar Harbor, ME, USA). Animals
were provided food and water ad libitum. Blood was ob-
tained from the retro-orbital sinus and 24-hour urines
were collected for monitoring the analytes described
below.
Treatment protocol
Diabetic mice were divided into two groups of five, one
of which received the compound designated 23CPPA and
the other of which served as the diabetic control. 23CPPA
is an orally administered small molecule of the heteroa-
cyl class containing an anionic side chain acetyl group
that interacts with positively charged, potentially glycat-
able, lysine amino groups in the albumin protein, and
thereby impedes the ability of glucose to nonenzymati-
cally condense with the protein [23]. The compound was
administered by gavage at a dose of 5 mg/kg twice per day
for 6 consecutive weeks, commencing when the animals
were approximately 9 weeks old. The dosage, timing of
initiation, and duration of treatment were based on pre-
vious work in this model [23]. Control animals received
saline gavage twice daily for the same period. At the con-
clusion of the experimental period, terminal blood and
urine samples were collected and the kidneys were har-
vested, transected, and snap frozen for subsequent ex-
amination of nephrin immunofluorescence and VEGF
immunostaining. Renal cortex from one half of one kid-
ney from each animal was separated by gross dissection
prior to freezing for subsequent analysis of TGF-b1 and
protein content.
Analytic and immunoassay procedures
Glucose was determined by the glucose oxidase
method (Sigma-Aldrich, St. Louis, MO, USA). Urine
albumin and type IV collagen were measured by com-
petitive enzyme-linked immunosorbent assay (ELISA)
performed according to the manufacturer’s instructions
(Exocell, Philadelphia, PA, USA). Glycated albumin
was determined by affinity chromatography on phenyl-
boronate agarose to separate nonglycated (unbound)
from glycated (bound) albumin. After eluting the bound
fraction with 0.3 mol/L sorbitol, its albumin concentration
was measured by an immunoassay specific for mouse al-
bumin. TGF-b1 was measured by immunoassay (R&D
Systems, Minneapolis, MN, USA) after acidification to
separate latency-associated peptide from the TGF-b1
dimers, allowing measurement of total TGF-b1 (active
plus latent component). The primary antibody in this as-
say has negligible cross-reactivity with TGF-b2 and TGF-
b3. VEGF was measured using a commercial ELISA kit
(R&D Systems) in which sample is added to microtiter
wells coated with an anti-VEGF antibody recognizing
VEGF120,164 and then sandwiched with a horseradish per-
oxidase (HRP)–conjugated anti-VEGF secondary anti-
body. Renal cortex was prepared for TGF-b1 and VEGF
assay by homogenization in 1 mL of lysis buffer [50
mmol/L Tris HCl, pH 7.5, 150 mmol/L NaCl, 0.05%
NP-40, proteinase inhibitor cocktail, and 0.5 mmol/L
phenylmethylsulfonyl fluoride (PMSF)], refrigeration for
15 minutes, centrifugation at 10,000g for 10 minutes, and
collection of the supernatant which was stored frozen un-
til assayed.
Immunofluorescence
Frozen kidney was embedded in Tissue-Tek (Sakura
Finetek, Torrance, CA, USA) 22-oxacalcitriol (OCT)
medium and cut on a cryostat microtome into 4 lm sec-
tions. For nephrin immunofluorescence, sections were
incubated overnight with affinity-purified rabbit poly-
clonal antibody directed against the cytoplasmic domain
of mouse nephrin (gift of Dr. L. Holzman, University
of Michigan) at a 1:100 dilution. For VEGF immunos-
taining, the primary antibody was rabbit anti-VEGF
(NeoMarkers/Lab Vision, Fremont, CA, USA). Im-
munofluorescence was developed with Cy3-conjugated
antirabbit antibody (1:1000 dilution), and glomeruli were
photographed under the same magnification (600×)
for identical development times (100 msec). For im-
munostaining, endogenous peroxidases were quenched
with 2.25% H2O2, and sections were blocked with
avidin/biotin (Vectra Blocking Kit) (Vector Laboratory,
Burlingame, CA, USA). The sections were then in-
cubated overnight with primary antibody followed by
development with biotinylated secondary antibody,
avidin-conjugated HRP, and diaminobenzidine (DAB)
peroxidase substrate. Nonspecific staining was assessed
in all analyses by omitting the primary antibody. Pho-
tomicrographs were read by an observer unaware of the
experimental group from which they were derived. Grad-
ing of intensity of immunofluorescence and of immunos-
taining was first performed on a visual basis on a scale of
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Table 1. Experimental animal data
Baseline Final
Body weight g
db/m 20.9 ± 0.5 23.0 ± 0.3
db/db control 40.6 ± 1.1a 45.0 ± 3.1a
db/db treated 34.0 ± 1.4a 40.0 ± 1.4a
Glucose mg/dL
db/m 85 ± 9 92 ± 8
db/db control 400 ± 30a 623 ± 42a
db/db treated 410 ± 35a 642 ± 38a
Glycated albumin lg/mL
db/m 491 ± 162 501 ± 139
db/db control 731 ± 59a 1128 ± 116a
db/db treated 703 ± 75a 652 ± 18a,b
Kidney weight mg
db/m – 236 ± 4
db/db control – 380 ± 22a
db/db treated – 298 ± 16a,b
aP < 0.05 vs. db/m; bP < 0.05 vs db/db control.
0 to 4+, followed by quantitative assessment with com-
puter programs (Scion Image, Frederick, MD, USA).
Immunoblotting
Equal amounts of lysates of renal cortex were sub-
jected to sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) (3% to 8% gradient) (Nu-
Page precast gels) (Invitrogen, Carlsbad, CA, USA) and
wet transferred to nitrocellulose membranes (Bio-Rad,
Hercules, CA, USA). The membranes were blocked
in 5% nonfat milk in Tris-buffered saline/0.1% Tween-
20 and probed overnight at 4◦C with the rabbit anti-
mouse nephrin antibody described above. After washing
with Tris-buffered saline/0.1% Tween-20, the membranes
were probed with HRP-conjugated antirabbit antibody
and chemiluminescence was developed with SuperSig-
nal West Pico substrate (Pierce Biotechnology, Rockford,
IL, USA). The membranes were reprobed with b-
actin (Sigma Chemical Co., St. Louis, MO, USA) to
correct for small differences in loading. The density
of the developed bands on the films was quantitated
using computer-assisted video densitometry (National
Institutes of Health, Bethesda, MD, USA).
RESULTS
General characteristics of the experimental animal
groups conformed with those known to be associated
with this model (Table 1). Body weights were greater
and blood glucose concentrations were higher in the dia-
betic db/db compared to the nondiabetic db/m controls.
Glucose was unaffected by the treatment protocol, indi-
cating that the compound did not influence glycemic sta-
tus. Nevertheless, diabetic mice receiving 23CPPA exhib-
ited significant lowering of the elevated concentrations of
serum glycated albumin that were observed in the con-





















Fig. 1. Urinary albumin excretion at initiation (baseline) and conclu-
sion (final) of experimental protocol in nondiabetic (db/m), diabetic
(db/db) control, and diabetic receiving 23CPPA (db/db-Rx). Results
are mean ± SEM (N = 5 in each experimental group). ∗P < 0.05 vs.
db/m; #P < 0.05 vs. db/db control.
inhibited nonenzymatic glycation of this protein despite
prevailing hyperglycemia. Kidney weights at the end of
the study were significantly greater in diabetic mice com-
pared to the nondiabetic controls, but were significantly
less in the diabetic mice receiving test compound than in
the diabetic mice receiving saline (Table 1).
Urine albumin excretion was increased in db/db con-
trol compared to nondiabetic mice, with values compara-
ble to those reported in the literature [24–26]. Diabetic
mice receiving test compound showed a significant re-
duction in albumin excretion, with values about 50% less
than those of control diabetic mice at the end of the exper-
imental period (Fig. 1). The absence of complete normal-
ization of albumin excretion is consistent with the persis-
tent hyperglycemia in these animals. Body weights were
similar in treated versus control diabetic mice, indicat-
ing that the decrease in albumin excretion did not reflect
caloric deprivation and could be ascribed to administra-
tion of 23CPPA. Breyer et al [27] consider albuminuria
as the best functional surrogate for severity of diabetic
nephropathy in this model, although they also note that
the degree of albuminuria does not consistently increase
with increasing duration of diabetes, as is often found in
human diabetes.
Urinary levels of type IV collagen also were signifi-
cantly higher in diabetic control compared to nondia-
betic mice, and were significantly less in diabetic ani-
mals receiving test compound than in control diabetic
mice receiving saline (Fig. 2). Urinary excretion of colla-
gen IV has been shown to reflect renal overproduction
of this extracellular matrix protein and the associated























Fig. 2. Urinary type IV collagen excretion at initiation (baseline) and
conclusion (final) of experimental protocol in nondiabetic (db/m), di-
abetic (db/db) control, and diabetic receiving 23CPPA (db/db-Rx).
Results are mean ± SEM (N = 5 in each experimental group). ∗P <
















Fig. 3. Renal transforming growth factor-b1 (TGF-b1) protein content
in nondiabetic (db/m), diabetic (db/db) control, and diabetic receiving
23CPPA (db/db-Rx). Renal cortex was homogenized in lysis buffer
containing proteinase inhibitors and processed as described in the text.
∗P < 0.05 vs. db/m; #P < 0.05 vs. db/db control.
mesangial expansion, glomerular occlusion, and loss of
filtration function in both human and rodent diabetes
[28–33].
TGF-b1 content in the renal cortex harvested at the
end of the experimental period was significantly higher in
tissue from diabetic controls compared to nondiabetic an-
imals. This increase was not observed in specimens from
db/db animals treated with test compound (Fig. 3). Thus,
changes in translated TGF-b1 protein correspond with
changes in TGF-b1 mRNA, which in situ hybridization
studies have shown is increased in glomeruli from db/db
mice and is reduced in glomeruli from diabetic animals
treated with 23CPPA [23].
Nephrin immunofluorescence was identified in a
glomerular-specific pattern in both db/m (Fig. 4A and B)
and db/db mice (Fig. 4C and D). There was no nephrin
immunoreactivity in Bowman’s capsule in any of the
sections, and sections incubated without the primary
antinephrin antibody were completely negative. On vi-
sual inspection, fluorescence intensity was diminished in
glomeruli from db/db controls compared to nondiabetic
mice, with mean respective grades of 1+ and 4+, whereas
the mean intensity grade was 3+ in glomeruli from db/db
mice treated with test compound (Fig. 4E and F). Quan-
titative assessment with image analysis confirmed that
nephrin immunofluorescence was reduced in glomeruli
from diabetic controls and was significantly greater in
treated diabetic mice, with values not significantly dif-
ferent from those observed in the nondiabetic animals
(Fig. 5). Western blot analysis of nephrin in renal extracts
showed the expected band at ∼185 kD under reducing
conditions (not depicted). The intensity of the bands com-
pared to db/m control, assigned an arbitrary value of 1.00
(± 0.16) for the relative ratio of nephrin:actin band inten-
sity, was decreased in samples from db/db control animals
(0.71 ± 0.09), whereas values in samples from db/db mice
receiving test compound (1.07 ± 0.19) did not differ from
those observed in nondiabetic controls.
Immunostaining of VEGF showed a diffuse pattern
in specimens from both db/m and db/db mice. No stain-
ing was observed in sections incubated without the pri-
mary anti-VEGF antibody. The intensity of glomerular
immunostaining was visibly increased in diabetic con-
trol (Fig. 6B) compared to nondiabetic mice (Fig. 6A),
with respective mean grades of 4+ and 1+, whereas the
mean intensity grade was 2+ in diabetic mice receiving
test compound (Fig. 6C). This difference was confirmed
with quantitation by density scanning, which indicated
that VEGF immunoreactivity was significantly greater in
diabetic controls and significantly less in treated diabetic
mice, with intensity values approaching those observed in
nondiabetic mice (Fig. 7). Immunoassay of VEGF protein
in renal extracts showed that, compared to nondiabetic
controls (680 ± 50 pg/mg protein), levels were increased
in control diabetic samples (800 ± 65 pg/mg protein),
whereas values in samples from diabetic mice receiving
test compound (620 ± 90 pg/mg) did not differ from those
observed in nondiabetic controls.
DISCUSSION
The results of this study causally implicate increased
glycated albumin in the development of abnormalities
contributory to diabetic nephropathy. Glomerular deple-
tion of the nephrin protein and overexpression of VEGF




Fig. 4. Representative photomicrograph
of nephrin protein immunofluorescence in
glomeruli from nondiabetic (db/m) (A and
B), diabetic control (db/db) (C and D),
and diabetic treated (db/db-Rx) (E and F)
mice. Sections (4 lm) were incubated with
affinity-purified rabbit antimouse antibody
that recognizes cytoplasmic domain of
mouse nephrin, followed by incubation with
Cy3-conjugated antirabbit antibody.
accompany the increased urinary excretion of albumin
and collagen IV that characterizes diabetic db/db mice,
and all four abnormalities are attenuated by administra-
tion of a compound that impedes the accelerated nonen-
zymatic glycation of albumin found in hyperglycemic di-
abetic animals. These findings are consistent with the hy-
pothesis that an elevated concentration of glycated al-
bumin contributes to podocyte damage in diabetes, and
give in vivo relevance to the in vitro observation that ex-
posure of epithelial cells in culture to glycated albumin
decreases nephrin expression [8]. The results further im-
plicate glycated albumin in the genesis of the increased
glomerular VEGF that is found in diabetes, likely related
to the glycated albumin-induced production of TGF-b1
[18, 21, 23], which itself is a potent stimulus of VEGF
secretion [34]. The reduction in renal TGF-b1, VEGF
expression, and urinary albumin and type IV collagen
in response to 23CPPA is consistent with reports that
anti-VEGF therapy reduces albuminuria in rodents [35,
36], that podocytes are the major source of VEGF in the
glomerulus [37], and that podocyte-derived VEGF may
operate in an autocrine loop to promote collagen IV pro-
duction, altering the permeability of the filtration barrier
[38, 39].
The mechanisms underlying changes in nephrin ex-
pression and their relationship to proteinuric disease
have not been fully elucidated. Nephrin expression has
been described as being transiently increased early in ex-
perimental diabetes [6, 7], perhaps due to activation of
PKC [40], but with longer duration of experimental dia-
betes and increasing glomerular injury, nephrin expres-
sion declines [6, 7], as found in the present study. These
changes with time are not understood, but it has been
suggested that the early increase is an acute response to
injury whereas the later decrease reflects progressive cell
damage and loss of function.
The role of TGF-b1 in proteinuria is unclear. Although
lessening of albuminuria was observed with reduction



















Fig. 5. Quantitative image analysis of immunofluorescence intensity
of nephrin protein in glomeruli from db/m, db/db control, and db/db
mice treated with 23CPPA (db/db-Rx). Results expressed as arbitrary
fluorescence intensity units. Sections were coded and read by an ob-
server unaware of the experimental group from which they derived.
Two to four glomeruli in each animal in each experimental group were
evaluated. ∗P < 0.05 vs. db/m; #P < 0.05 vs. db/db control.
of glomerular TGF-b1 mRNA with 23CPPA treatment
[23], the same reduction of TGF-b expression with a
neutralizing anti-TGF-b antibody in db/db mice did
not lessen albuminuria even though it ameliorated the
accumulation of extracellular matrix proteins [41]. Po-
tential explanations for this dichotomy include a greater
importance of nephrin in the permeability changes
responsible for proteinuria [42], the possibility that
glycated albumin independently affects permeability
properties of the glomerular filtration barrier [43], and/or
that proteinuria promotes progression of renal disease
through activation of the tubulointerstitial TGF-b
system [44, 45]. Also of interest in this context is the
report that high glucose-induced activation of PKC-a
leads to increased TGF-b1 expression [46], and the
recent findings of Menne et al [47] that streptozotocin-
diabetic mice deficient in PKC-a were protected from
albuminuria even though glomerular TGF-b1 expression
was not significantly different from that in wild-type
mice. This group presented further evidence from
studies in the PKC-a–deficient model suggesting that
albuminuria is mediated via down-regulation of the
negatively charged basement membrane heparan sulfate
proteoglycan, perlecan, and that this abnormality relates
to PKC-a–dependent up-regulation of VEGF165 and
its receptor flk-1. Additionally, attempts to understand
the influence of renal TGF-b1 on albuminuria should
take into account the effects of TGF-b1 on VEGF and
of VEGF on albuminuria. It is worth noting that in the
anti-TGF-b treated db/db mice discussed above, VEGF
mRNA expression in the renal cortex was not diminished
despite antagonism of TGF-b [41]. Perhaps VEGF over-
expression was sustained by other features of the diabetic




Fig. 6. Representative photomicrograph of vascular endothelial
growth factor (VEGF) protein immunostaining in glomeruli from non-
diabetic (db/m) (A), diabetic control (db/db) (B), and diabetic-treated
(db/db-Rx) (C) mice. Sections (4 lm) were incubated with rabbit anti-
VEGF antibody, followed by incubation with biotinylated antirabbit
antibody, avidin-conjugated horseradish peroxidase (HRP), and di-
aminobenzidine (DAB) peroxidase substrate.

















Fig. 7. Quantitative density scanning of immunostaining intensity of
vascular endothelial growth factor (VEGF) protein in glomeruli from
db/m, db/db control, and db/db mice treated with 23CPPA (db/db-Rx).
Results expressed as arbitrary intensity units. Sections were coded and
read by an observer unaware of the experimental group from which they
derived. Three to five glomeruli in each animal from each experimental
group were evaluated. ∗P < 0.05 vs. db/m; #P < 0.05 vs. db/db control.
glycated albumin concentrations, consistent with the fail-
ure of anti-TGF-b antibody, and the success of 23CPPA in
dampening renal VEGF expression in diabetes. Further-
more, these divergent effects on glomerular VEGF could
explain the antiproteinuric response to 23CPPA versus
anti-TGF-b antibody.
CONCLUSION
We provide evidence that decreased nephrin protein
and increased VEGF expression in the glomeruli of di-
abetic db/db mice accompany the increased protein ex-
cretion that is characteristically observed in diabetes, and
that these abnormalities are attenuated by administration
of a compound that impedes the accelerated Amadori
modification of albumin that is associated with the dia-
betic state. The results indicate that glycated albumin con-
tributes to podocyte damage in diabetes, perhaps through
one or more of the pathologic mechanisms proposed by
Mundel and Shankland [48] (i.e., interference with the
slit diaphragm complex and its lipid raft; abnormalities
in the podocyte-glomerular basement membrane inter-
action; abnormalities of the actin cytoskeleton and asso-
ciated proteins such as a-actinin-4; and alterations in the
apical domain of the podocyte, such as neutralization of
negative cell surface charges). Podocyte damage and loss
are believed to be critical determinants in the develop-
ment of glomerulosclerosis and the resultant progressive
renal failure [49], possibly arising from diminished ten-
sile support to the underlying glomerular capillary loop
and lack of the opposing force to hydrostatic capillary
pressure that can lead to basement membrane denuda-
tion, outward bulging of the capillary loop, synechiae
formation, inspissated proteins, hyalinosis, and progres-
sive scarring [50–55]. In this context, the present findings
afford an explanation for the antialbuminuric effects of
23CPPA and for the reported ability of this agent to arrest
the development of glomerulosclerosis and renal insuffi-
ciency [23].
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